Skip to main content
Erschienen in:

01.04.2021 | Pharmacoepidemiology and Prescription

Patients’ contribution to drug safety in Catalonia: the interest of personal feelings on adverse drug reactions

verfasst von: J. Riera-Arnau, L. A. Alvarado Aguirre, N. Garcia Doladé, X. Vidal Guitart, A. Figueras, G. Cereza García

Erschienen in: European Journal of Clinical Pharmacology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There are few studies on the personal view retrieved by patients in the spontaneous reports’ free-text section of suspected adverse drug reactions.

Methods

We analysed the suspected adverse drug reactions (ADRs) spontaneous reports sent to the Catalan Centre of Pharmacovigilance between 2013 and 2017. The information provided in the free-text section was classified as (1) temporal sequence, (2) description of symptoms, (3) description of psychological impact, (4) withdrawal effects, (5) alternative causes, and (6) rechallenge. The concordance level between the perceived severity by the reporter and the pharmacovigilance team was assessed by the Kappa index (ƙ). Usual descriptive statistics were used to describe variables.

Results

Nationally, 190 spontaneous reports described 383 ADRs, which 28.6% were unknown or poorly known in the literature, and 52.1% were serious. The most frequent ADRs were gastrointestinal (19.3%) and neurological (19.1%), and among the most common 213 suspected medicines, there were those used for nervous system conditions (18.8%). The agreement on the perception of ADRs’ severity between citizens and centre’s technicians was ‘good’ (K = 0.62 (0.51–0.72)). An analysis of the free-text section of reports showed that one-quarter of the reports provided useful additional data, like the psychobiosocial impact, which could explain the discrepancy between patients and health professionals in the classification of the severity of some ADRs.

Conclusions

Patients’ report free-text section provides relevant information, mainly about symptoms description, psychobiosocial impact and feelings. Therefore, it is a section to be enhanced and analysed. These findings should encourage the strengthening of citizens reporting.
Literatur
1.
Zurück zum Zitat Raine JM (2012) Drug safety: reporting systems for the general public. BMJ 354:e4916CrossRef Raine JM (2012) Drug safety: reporting systems for the general public. BMJ 354:e4916CrossRef
2.
Zurück zum Zitat Hazell L, Cornelius V, Hannaford P, Shakir S, Avery AJ, Yellow Card Study Collaboration (2013) How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme. Drug Saf 36:199–206CrossRef Hazell L, Cornelius V, Hannaford P, Shakir S, Avery AJ, Yellow Card Study Collaboration (2013) How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme. Drug Saf 36:199–206CrossRef
3.
Zurück zum Zitat van Hunsel F, de Waal S, Härmark L (2017) The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015. Pharmacoepidemiol Drug Saf 26:977–983CrossRef van Hunsel F, de Waal S, Härmark L (2017) The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015. Pharmacoepidemiol Drug Saf 26:977–983CrossRef
4.
Zurück zum Zitat Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. (2011) Evaluation of patient reporting of adverse drug reactions to the UK ‘ Yellow Card Scheme ’: literature review , descriptive and qualitative analyses , and questionnaire surveys. Chapter 5 (study 3). Health Technol Assess (Rockv) 15 Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. (2011) Evaluation of patient reporting of adverse drug reactions to the UK ‘ Yellow Card Scheme ’: literature review , descriptive and qualitative analyses , and questionnaire surveys. Chapter 5 (study 3). Health Technol Assess (Rockv) 15
5.
Zurück zum Zitat Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘ Yellow Card Scheme ’: literature review , descriptive and qualitative analyses , and questionnaire surveys. Chapter 2 (study 1), Chapter 4 (study 2) and Chapter 6 (study 4). Health Technol Assess (Rockv) 2011;15 Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘ Yellow Card Scheme ’: literature review , descriptive and qualitative analyses , and questionnaire surveys. Chapter 2 (study 1), Chapter 4 (study 2) and Chapter 6 (study 4). Health Technol Assess (Rockv) 2011;15
7.
Zurück zum Zitat Härmark L, Raine J, Leufkens H, Edwards IR, Moretti U, Sarinic VM, Kant A (2016) Patient-reported safety information: a renaissance of pharmacovigilance? Drug Saf 39(10):883–890CrossRef Härmark L, Raine J, Leufkens H, Edwards IR, Moretti U, Sarinic VM, Kant A (2016) Patient-reported safety information: a renaissance of pharmacovigilance? Drug Saf 39(10):883–890CrossRef
8.
Zurück zum Zitat van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K (2012) Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf 35:45–60CrossRef van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K (2012) Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf 35:45–60CrossRef
9.
Zurück zum Zitat Inácio P, Cavaco A, Airaksinen M (2017) The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol 83:227–246CrossRef Inácio P, Cavaco A, Airaksinen M (2017) The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol 83:227–246CrossRef
10.
Zurück zum Zitat Strom BL, Kimmel SE, Hemnessy S (2012) Editors. Pharmacoepidemiology. UK, Wiley-Blackwell, fifth editionCrossRef Strom BL, Kimmel SE, Hemnessy S (2012) Editors. Pharmacoepidemiology. UK, Wiley-Blackwell, fifth editionCrossRef
11.
Zurück zum Zitat Anderson C, Krska J, Murphy E, Avery A, Yellow Card Study Collaboration (2011) The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol 72:806–822CrossRef Anderson C, Krska J, Murphy E, Avery A, Yellow Card Study Collaboration (2011) The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol 72:806–822CrossRef
12.
Zurück zum Zitat Salgueiro E, Jimeno FJ, Aguirre C, García M, Ordóñez L, Manso G (2013) Direct reporting by patients of adverse drug reactions in Spain. Farm Hosp 37(1):65–71 Salgueiro E, Jimeno FJ, Aguirre C, García M, Ordóñez L, Manso G (2013) Direct reporting by patients of adverse drug reactions in Spain. Farm Hosp 37(1):65–71
14.
Zurück zum Zitat Aguirre C, García M (2016) Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system. Med Clin (Barc) 147:461–464CrossRef Aguirre C, García M (2016) Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system. Med Clin (Barc) 147:461–464CrossRef
15.
17.
Zurück zum Zitat CIOMS current challenges in pharmacovigilance: pragmatic approaches. Report of CIOMS Working Group V. Geneva: Council for International Organizations of Medical Sciences. 2001;III:99–108 CIOMS current challenges in pharmacovigilance: pragmatic approaches. Report of CIOMS Working Group V. Geneva: Council for International Organizations of Medical Sciences. 2001;III:99–108
18.
Zurück zum Zitat Matos C, van Hunsel F, Joaquim J (2015) Are consumers ready to take part in the pharmacovigilance system?--a Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol 71:883–890CrossRef Matos C, van Hunsel F, Joaquim J (2015) Are consumers ready to take part in the pharmacovigilance system?--a Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol 71:883–890CrossRef
19.
Zurück zum Zitat van Hunsel F, Talsma A, van Puijenbroek E, de Jong-van den Berg L, van Grootheest K (2011) The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf 20:286–291CrossRef van Hunsel F, Talsma A, van Puijenbroek E, de Jong-van den Berg L, van Grootheest K (2011) The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf 20:286–291CrossRef
20.
Zurück zum Zitat van Hunsel F, Passier A, van Grootheest AC (2009) Comparing patients’ and healthcare professionals’ ADR reports after media attention. The broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol 67:558–564CrossRef van Hunsel F, Passier A, van Grootheest AC (2009) Comparing patients’ and healthcare professionals’ ADR reports after media attention. The broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol 67:558–564CrossRef
21.
Zurück zum Zitat Hammond IW, Rich DS, Gibbs TG (2007) Effect of consumer reporting on signal detection: using disproportionality analysis. Expert Opin Drug Saf 6:705–712CrossRef Hammond IW, Rich DS, Gibbs TG (2007) Effect of consumer reporting on signal detection: using disproportionality analysis. Expert Opin Drug Saf 6:705–712CrossRef
22.
Zurück zum Zitat de Langen J, van Hunsel F, Passier A, de Jongvan den Berg LTW, van Grootheest AC (2008) Adverse drug reaction reporting by patients in the Netherlands, three years of experience. Drug Saf 31:515–524CrossRef de Langen J, van Hunsel F, Passier A, de Jongvan den Berg LTW, van Grootheest AC (2008) Adverse drug reaction reporting by patients in the Netherlands, three years of experience. Drug Saf 31:515–524CrossRef
23.
Zurück zum Zitat McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, Avery A, Yellow Card Collaboration (2010) Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf 33:775–788CrossRef McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, Avery A, Yellow Card Collaboration (2010) Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf 33:775–788CrossRef
25.
Zurück zum Zitat Bergvall T, Noren GN, Lindquist M (2014) vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf 37:65–77CrossRef Bergvall T, Noren GN, Lindquist M (2014) vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf 37:65–77CrossRef
27.
Zurück zum Zitat Butlletí de Farmacovigilància de Catalunya: Notificació de sospites de reaccions adverses a medicaments: incorporació dels ciutadans. Generalitat de Catalunya, Departament de Salut [Internet]. 2013;11(1). Accessed January 17, 2019 Butlletí de Farmacovigilància de Catalunya: Notificació de sospites de reaccions adverses a medicaments: incorporació dels ciutadans. Generalitat de Catalunya, Departament de Salut [Internet]. 2013;11(1). Accessed January 17, 2019
Metadaten
Titel
Patients’ contribution to drug safety in Catalonia: the interest of personal feelings on adverse drug reactions
verfasst von
J. Riera-Arnau
L. A. Alvarado Aguirre
N. Garcia Doladé
X. Vidal Guitart
A. Figueras
G. Cereza García
Publikationsdatum
01.04.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Pharmacology / Ausgabe 4/2021
Print ISSN: 0031-6970
Elektronische ISSN: 1432-1041
DOI
https://doi.org/10.1007/s00228-020-03033-5